methylation reached nadir at best response and gradually increased thereafter. An elevation of mutation AF or the emergence of new mutation(s) (molecular PD) was observed in 4 patients prior to PD assessed by imaging. In all patients, an elevation of DNA methylation was observed prior to PD assessed by imaging; among them, 3 had changes in DNA methylation prior to molecular PD, suggesting DNA methylation may be a more sensitive biomarker. Conclusion: Collectively, our study demonstrates DNA methylation, continuously increasing from the nadir (best response), can be utilized as a biomarker for treatment monitoring.
Background: This study aimed to investigate the correlation of Octamer-4 (OCT4) expression with clinicopathological features and prognosis in lung adenocarcinoma patients, and to further explore the killing effect of OCT4 specific cytotoxic T cells (CTLs) on lung cancer stem cells (LCSCs). Method: 257 lung adenocarcinoma patients underwent thoracic surgery were enrolled in this study and tissue samples were obtained during the operation. OCT4 expression was detected by immunofluorescence staining assay. CD154 + feeder cells were constructed to transfect CD40-B cells, and then mixed with OCT4 antigen peptides and CD8 + T lymphocytes extracted from peripheral blood of lung adenocarcinoma patients, subsequently the OCT4 specific CTLs were co-cultured with PC9 LCSCs to detect the killing efficacy. OCT4 + phenotype was illuminated to be associated with poor differentiation, worse disease free survival (DFS) and overall survival (OS). And Cox's analysis revealed OCT4 + was an independent predictive factor for shorter DFS and OS. Result: CD40-B-cells with antigen presenting capacity was successfully constructed indicated by elevated CD86 + , human leukocyte antigens (HLA)-A + and CD80 + cells percentage, and OCT4 specific CTLs was successfully activated suggested by increased CD3 + , CD4 + and CD8 + cells percentage as well as elevated interleukin (IL-2) and interferon (IFN)-g expressions. OCT4 specific CTLs presented an elevated cytotoxic activity on LCSCs at percentage 75.5% ± 8.2% compared with CMV pp65 CTLs (25.6% ± 5.1%) and blank control CTLs (20% ± 4.7%). Conclusion: In conclusion, OCT4 expression could be served as a convincing risk biomarker for prognosis in lung adenocarcinoma patients and potential target of CTLs as immuntherapy in killing LCSCs. Keywords: Octamer-4 (OCT4), lung adenocarcinoma, Prognosis P2.04-01 Associations Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells.
G. Cruz-Rico, 1 X. Popa Navarro, 1 A. Avilés-Salas, 1 K.Y. Flores-Vélez, 1 A. Cardona, 2 L. Ramírez-Tirado, 1 E. Vergara, 1 F. Barron, 3 L.A. Cabrera-Miranda, 1 O. Arrieta 3 1 Instituto Nacional de Cancerología, México/MX, 2 Clinical and Translational Oncology Group, Foundation for Clinical and Applied Cancer Research -Ficmac, Bogotá/ CO, 3 National Cancer Institute, Mexico City/MX Background: The analysis by immunohistochemistry (IHC) of the programmed cell death-ligand 1 (PD-L1) protein expression is the most extensively explored biomarker for response to immunotherapy in non-small cell lung cancer (NSCLC). However, there are differences concerning diverse IHC assays and cut-off criteria: Pembrolizumab with the 22C3 assay with cut-off ranges of >1%, 1-49% and >50%; and Nivolumab with the 28-8 assay and ranges of <1%, 1-5%, 5 -10% and >10%. Furthermore, there is lack of information regarding the association between the histological subtype of adenocarcinoma and PD-L1 expression. In this work, we assessed the frequency of PD-L1 expression according with to histological subtype of adenocarcinoma. Method: PD-L1 expression was assessed using the PD-L1 IHC 22C3 pharmDx immunohistochemistry assay (Dako North America, Inc.). We correlated histological subtype of adenocarcinoma with the frequency and intensity of PD-L1 expression, smoking history, EGFR and ALK status. Result: Tissue samples from one hundred and sixty-two were analyzed, of which 33 (20.4%) were excluded due to insufficient material for PD-L1asessment. Among them, 106 patients (71,55%) were female, the median age was 63 years (range 31-86 years), 69 (53.5%) were never-smokers with no exposition to wood smoke or asbestos (79,61.2% and 117, 90.7% respectively). Among the 129 adenocarcinomas, 31.0% were acinar histological subtype; 27.1% solid, 17.1% papillary, 3.9% lepidic, 1.6% micropapillary and 54.3% had a moderated tumor differentiation grade. According to PD-L1 score, 49 (38%) of the patients were classified as negative (PD-L1<1%), 71(55%) as poor PD-L1 expression (1 -49%), and 9 (7%) as strong PD-L1 expression (50%). According to the IASLC/ATS adenocarcinoma histological subtype was associated with PD-L1 expression (p¼0.003). Solid and acinar adenocarcinomas were more likely to present strong PD-L1 expression (55.6% and 33.3%, respectively) compared to lepidic, papillary, micropapillary and unspecified tumors, which presented a strong PD-L1 expression in up to 11.1%. Median PFS to first line therapy was 10.3 (95% CI: 6.1e14.5) months. Tobacco exposure was the only factor independently associated with an increase in the hazard of progression to first line therapy (either CT or TKI) from any cause among NSCLC patients (HR, 95% CI: 1.56-12.1). The median OS was 41.9 (95% CI: 10.9e72.9) months. Median OS differences were not found among PD-L1 (negative vs. positive: 60.6 vs. 31.3 months, p¼0.685). Conclusion: Patients with adenocarcinoma tumors, solid histological subtype and poor differentiation grade can be more benefited with a PD-1 based immunotherapy. PD-L1 score can be a predictor factor for the response to first line chemotherapy. Background: Immunotherapy represents a dramatic change in the treatment of non small cell lung cancer (NSCLC), but nowadays prognostic and predictive factors of response to immune checkpoint inhibitors (ICIs) are still under debate. It has been observed that circulating biomarkers might have a prognostic role in lung cancer. The aim of this study was to determine whether circulating tumor cells (CTCs) as well as circulating free DNA (cfDNA) might predict the outcome of patients with advanced NSCLC treated with Nivolumab. Method: From May 2015 to April 2017 89 NSCLC patients were treated with Nivolumab as a second or further line of therapy. All patients underwent blood sample collection before the start of treatment (baseline) and after 4 and 7 cycles of Nivolumab to evaluate both biomarkers. CTCs were isolated from 3mL of blood by the
